Core Viewpoint - The biotechnology and innovative pharmaceutical industry in China has experienced volatility due to previous overvaluation, uncertainty in national medical insurance drug pricing, delays in business expansion expectations, and year-end fund sell-offs [1] Group 1: Market Conditions - Market liquidity remains robust, making valuations of quality companies increasingly attractive [1] - Ongoing business expansion activities are noted, with the potential for large transactions still possible [1] - Further downside price risk appears limited, indicating a healthy consolidation phase [1] Group 2: Company-Specific Insights - For CSPC Pharmaceutical Group (01093), delays in business expansion execution have weakened investor confidence, creating more attractive buying opportunities [1] - Assuming business expansion resumes as expected, the price-to-earnings (P/E) valuation remains very attractive for CSPC [1] - The third-quarter performance may serve as a recent catalyst for CSPC [1] Group 3: Future Outlook - The likelihood of significant progress on large business expansion transactions is high for next year [1] - For China National Pharmaceutical Group (01099), improvements in accounts receivable days and the initiation of the "14th Five-Year Plan" will support the recovery of profit momentum [1] - Current stock price levels offer an appealing dividend yield and low P/E ratio, with significant upside potential as operational efficiency continues to improve [1]

Core Viewpoint - The biotechnology and innovative pharmaceutical industry in China has experienced volatility due to high valuations from previous increases, uncertainty in national medical insurance drug pricing, delays in business expansion expectations, and year-end fund sell-offs [1] Industry Summary - The market liquidity remains robust, making valuations of quality companies increasingly attractive [1] - Business expansion activities are ongoing, with the potential for large transactions still possible, and further downside price risks appear limited [1] - The rising proportion of innovative drugs and accelerated profit growth indicate that the current pullback is a healthy consolidation, providing attractive opportunities for deployment in the coming year [1] Company Summary - For CSPC Pharmaceutical Group (01093), delays in business expansion execution have weakened investor confidence, creating a more attractive buying opportunity [1] - Assuming business expansion resumes as expected, the price-to-earnings ratio remains very attractive [1] - The possibility of completing several smaller business expansion transactions before year-end is still likely, with Q3 performance potentially serving as a recent catalyst [1] - For Sinopharm Group (01099), improvements in accounts receivable days and the initiation of the "14th Five-Year Plan" will support the recovery of profit momentum [1] - Current stock price levels offer an appealing dividend yield and a low price-to-earnings ratio, with significant upside potential as operational efficiency continues to improve [1]

Market Overview - The market sentiment was boosted by progress in US-China trade talks, leading to a rise in Hong Kong's three major indices, with the Hang Seng Index increasing by 1.05% to 26,433.7 points and a total trading volume of HKD 267.08 billion [1] - According to China Merchants Securities, the recent adjustments in the Hong Kong market were seen as excessive, and the easing of the trade war along with incremental policy releases are expected to support a rebound in the market [1] Blue-Chip Stocks Performance - WuXi AppTec (02359) saw a significant increase of 4.07%, closing at HKD 115, contributing 3.09 points to the Hang Seng Index, with a revenue of RMB 32.86 billion for the first three quarters of 2025, up 18.6% year-on-year, and a net profit of RMB 12.076 billion, up 84.84% [2] - Other notable blue-chip stocks included Baidu Group-SW (09888) rising by 6.2% to HKD 125.1, and Semiconductor Manufacturing International Corporation (00981) increasing by 3.5% to HKD 82.8 [2] Sector Highlights - Large technology stocks experienced gains, with Baidu up over 6%, Alibaba up over 3%, and Tencent up 2.9%, driven by preliminary agreements on tariffs between the US and China [3] - The cryptocurrency market surged, with Bitcoin surpassing USD 115,000, and related stocks performing well, such as New Fire Technology Holdings (01611) up 17.81% [3] - Semiconductor stocks also saw a rise, with InnoCare Pharma (02577) increasing by 12.73% and Huahong Semiconductor (01347) up 4.98% [4] Nuclear Power Sector - The nuclear power sector showed strong performance, with Harbin Electric (01133) rising by 11.44% and China National Nuclear Power (02302) up 10.53%, supported by government initiatives for future industry development [6] Copper Industry Insights - The copper sector experienced a general increase, with China Daye Non-Ferrous Metals (00661) rising by 11.11%, driven by improved downstream purchasing and concerns over future supply tightness [7] Notable Stock Movements - Huaxin Cement (06655) rose by 10.23% after reporting a revenue of RMB 25.033 billion for the first three quarters of 2025, a 1.27% increase year-on-year [8] - Baidu Group-SW (09888) was highlighted for its transition towards AI, with a valuation shift expected as it integrates AI technology into its core business [9] - Guangqi Group (02238) reported a revenue decline of 10.49% year-on-year, resulting in a net loss of approximately RMB 4.312 billion for the first three quarters of 2025 [11]

Core Viewpoint - The Chinese biotechnology and innovative pharmaceutical industry has experienced volatility due to previous overvaluation, uncertainty in national medical insurance drug pricing, delays in business expansion expectations, and year-end fund sell-offs [1] Industry Summary - Market liquidity remains robust, making valuations of quality companies increasingly attractive [1] - Business expansion activities are ongoing, with the potential for large transactions still present, and further price downside risks appear limited [1] - The rising proportion of innovative drugs and accelerated profit growth indicate that the current pullback is a healthy consolidation, providing attractive opportunities for deployment in the coming year [1] Company Summary - For CSPC Pharmaceutical Group, delays in executing business expansion have weakened investor confidence, creating more attractive buying opportunities; assuming business expansion resumes as expected, its price-to-earnings ratio remains very appealing [1] - The company is expected to complete several smaller business expansion transactions before year-end, with third-quarter performance potentially serving as a recent catalyst [1] - For Sinopharm Group, improvements in accounts receivable days and the initiation of the 14th Five-Year Plan will support the recovery of profit momentum; the current stock price offers an attractive dividend yield and a low price-to-earnings ratio, indicating significant upside potential as operational efficiency continues to improve [1]

Core Insights - The highest short-selling ratios were observed for China Resources Beer (80291) and JD Health (86618), both at 100%, followed by JD Group (89618) at 93.32% [1][2] - The top three companies by short-selling amount were Xiaomi Group (01810) at 2.156 billion, Alibaba (09988) at 2.038 billion, and Tencent Holdings (00700) at 1.552 billion [1][3] - JD Group (89618) had the highest deviation value at 43.55%, indicating significant short-selling activity compared to its historical average [1][2] Short-Selling Ratios - China Resources Beer (80291) and JD Health (86618) both recorded a short-selling ratio of 100% [2] - JD Group (89618) had a short-selling ratio of 93.32% [2] - Other notable companies included Anta Sports (82020) at 87.40% and BYD Company (81211) at 81.07% [2] Short-Selling Amounts - Xiaomi Group (01810) led with a short-selling amount of 2.156 billion, followed by Alibaba (09988) at 2.038 billion and Tencent Holdings (00700) at 1.552 billion [3] - Other significant amounts included Meituan (03690) at 1.461 billion and SMIC (00981) at 1.335 billion [3] Deviation Values - JD Group (89618) had the highest deviation value at 43.55%, indicating a significant difference from its average short-selling ratio [2][3] - Other companies with notable deviation values included SenseTime (80020) at 31.62% and China Resources Beer (80291) at 31.60% [2][3]

Core Viewpoint - The eleventh batch of national organized drug procurement has commenced, involving over 400 companies and covering 55 drug varieties, with a focus on quality control and fair competition in pricing [1] Group 1: Procurement Details - The procurement process started at 7:30 AM in Qingpu District, Shanghai, with public disclosure of application information at 10:30 AM [1] - The procurement includes significant products such as cefoperazone injection and dapagliflozin oral sustained-release formulation, projected to achieve sales in the billions for 2024 [1] - Major pharmaceutical companies like Heng Rui Medicine, Qilu Pharmaceutical, and AstraZeneca are participating with multiple products [1] Group 2: Procurement Rules - The new procurement rules emphasize "stabilizing clinical use, ensuring quality, preventing internal competition, and avoiding collusion" [1] - For the first time, medical institutions are allowed to report quantities based on brand names, enhancing the focus on quality control [1] - Each participating company must commit to pricing no lower than their costs, with lower-priced bids requiring a justification for their pricing to promote healthy market competition [1]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [1] Core Insights - The report highlights significant advancements in innovative drugs, particularly in the context of recent clinical trial results presented at the 2025 ESMO conference, showcasing the potential for new treatment options in various cancer types [12][19] - The report emphasizes the emergence of domestic drugs that have achieved notable efficacy in treating conditions such as NSCLC and HER2-positive breast cancer, indicating a shift in the competitive landscape [13][17] Summary by Sections 1. New Drug Developments - **2L EGFR Mutant NSCLC**: The drug Lukanosumab (sac-TMT) is the first to demonstrate both overall survival (OS) and progression-free survival (PFS) benefits in patients with TKI-resistant NSCLC, with mPFS of 8.3 months compared to 4.3 months for chemotherapy [13][14] - **HER2 Positive Breast Cancer**: The drug Ruikang Trastuzumab shows longer mPFS of 30.6 months compared to 8.3 months for the chemotherapy combination, indicating a promising new option for patients [17][18] - **T-Bren for Breast Cancer**: Early data from the T-Bren trial shows a clinical overall response rate (cORR) of 82.2% in HER2-positive patients, with mPFS of 18.0 months [19][20] - **2L HER2 Positive Gastric Cancer**: Anniotuzumab combined with chemotherapy shows significant improvements in mPFS (7.1 months vs 2.7 months) and mOS (19.6 months vs 11.5 months), suggesting a potential shift in treatment paradigms [21][24] 2. Market Performance - The pharmaceutical and biotechnology sector saw a 0.58% increase in October, underperforming the CSI 300 index by 2.67 percentage points, ranking 25th among 31 sub-industries [25][30] - The medical research outsourcing sector experienced the highest growth, up 5.47%, while other bioproduct sectors faced declines [30][34]

Investment Rating - The report maintains an investment rating of "Outperform" with a rating of A [5] Core Insights - The report highlights the significant performance of domestic new drugs showcased at the ESMO 2025 conference, with several companies presenting excellent clinical data [3][21] - The report emphasizes the importance of academic conferences as key catalysts for the innovative drug sector, particularly mentioning ESMO, ASCO, and WCLC as critical events for Chinese pharmaceutical companies [20] Weekly New Drug Market Review - From October 20 to October 26, 2025, the top five gainers in the new drug sector were: - 欧康维视 (+8.87%) - 君圣泰 (+8.21%) - 诺思兰德 (+7.07%) - 友芝友 (+4.42%) - 海创药业 (+3.73%) - The top five losers were: - 康宁杰瑞 (-17.72%) - 北海康成 (-14.42%) - 创胜集团 (-14.29%) - 宜明昂科 (-13.40%) - 来凯医药 (-12.40%) [16][17] Recommended Focus Stocks - The report suggests focusing on several stocks with potential catalysts, including: 1. Products with high overseas volume certainty after MNC certification: - PD-1 upgraded product: 三生制药 - GLP-1 asset: 联邦制药 - ADC assets: 科伦博泰, 百利天恒 2. Potential heavyweights for overseas MNC authorization: - PD-1 upgraded products: 康方生物, 信达生物 - Breakthroughs in autoimmune fields: 益方生物, 中国抗体 - Innovative target ADC: 复宏汉霖, 石药集团 3. Stocks likely to benefit from medical insurance negotiations and commercial insurance innovative drug directories: - Beneficiaries of medical insurance directory: 恒瑞医药, 康诺亚, 迈威生物, 智翔金泰, 海创药业 - Beneficiaries of commercial insurance innovative drug directory: 药明巨诺, 科济药业 [2][20] New Drug Approval and Acceptance - This week, four new drug or new indication applications were approved, and five new drug or new indication applications were accepted in the domestic market [9] - A total of 46 new drug clinical applications were approved, and 31 new drug clinical applications were accepted [10] Key Domestic Market Events - 信达生物 announced a global strategic partnership with Takeda to accelerate the development of new generation tumor immunotherapy and antibody-drug conjugate therapies [11] - 康宁杰瑞 and 石药集团 announced that their HER2 bispecific antibody-drug conjugate JSKN003 received breakthrough therapy designation from the CDE [11] - 和黄医药 presented clinical data for HMPL-A251 at the AACR-NCI-EORTC conference [11] Key Overseas Market Events - 罗氏 received FDA approval for Gazyva/Gazyvaro for the treatment of active lupus nephritis in adult patients [12] - Electra Therapeutics announced that its therapy ELA026 received breakthrough therapy designation from the FDA and PRIME qualification from the EMA [12] - 安斯泰来 announced that the FDA accepted its supplemental biologics license application for the antibody-drug conjugate Padcev in combination with Keytruda [12]

Group 1 - Southbound funds net bought HK stocks worth HKD 34.14 billion on October 24, with notable net purchases in Meituan (HKD 6.54 billion), SMIC (HKD 6.01 billion), CNOOC (HKD 5.7 billion), Tencent (HKD 3.75 billion), Xiaomi (HKD 2.98 billion), and Alibaba (HKD 1.7 billion) [1] - Southbound funds have continuously net bought SMIC for four days, totaling HKD 17.9796 billion, and Tencent for three days, totaling HKD 9.4926 billion, as well as CNOOC for three days, totaling HKD 29.7542 billion [3] Group 2 - CNOOC's largest offshore oil and gas platform in the Beibu Gulf, the Weizhou 11-4CEPD platform, completed land engineering on October 24 and has entered the offshore installation phase, with a total weight exceeding 14,000 tons and an annual processing capacity exceeding one million tons, which will enhance the region's oil and gas self-sufficiency [4] - Alibaba launched its first self-developed Quark AI glasses on October 24, featuring dual flagship chips from Qualcomm and Hengxuan, while Apple plans to release a competing AI glasses product by the end of 2026 [4] - The Chinese government emphasized the importance of technological modernization in its 14th Five-Year Plan, aiming to enhance independent innovation capabilities and seize opportunities in the new round of technological revolution and industrial transformation [4] Group 3 - A fire incident involving a Li Auto Mega vehicle occurred on October 23 in Shanghai, with the vehicle catching fire during normal operation without prior collision or impact [5][6]

Core Insights - On October 24, 2023, CSPC Pharmaceutical Group made its debut on the Hong Kong Stock Connect active trading list for the first time in a month [2][3] - The total trading volume of active stocks on the Hong Kong Stock Connect reached HKD 457.51 billion, accounting for 40.61% of the day's total trading amount, with a net buying amount of HKD 14.12 billion [2] - Among the active stocks, SMIC had the highest trading volume at HKD 103.55 billion, followed by Alibaba-W and Hua Hong Semiconductor with HKD 89.33 billion and HKD 54.03 billion respectively [2] Trading Activity Summary - CSPC Pharmaceutical Group recorded a trading volume of HKD 5.39 billion on the day, with a net sell amount of HKD 2.47 billion, and its stock price closed down by 3.90% [2][3] - The most frequently listed stocks in the past month include Alibaba-W and Hua Hong Semiconductor, each appearing 16 times, indicating strong interest from Hong Kong Stock Connect investors [2] - Other notable stocks on the active trading list include Tencent Holdings with a trading volume of HKD 35.65 billion and a net buying amount of HKD 3.75 billion, and Xiaomi Group-W with HKD 45.85 billion and a net buying amount of HKD 2.99 billion [2]